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The genetic component of colorectal cancer (CRC) predisposition
has been only partially explained. We recently suggested that
a subtle decrease in the expression of one allele of the TGFBR1
gene was a heritable quantitative trait predisposing to CRC. Here,
we reﬁned the measurements of allele-speciﬁc expression (ASE) of
TGFBR1 in a population-based series of CRC patients and con-
trols. Five single-nucleotide polymorphisms (SNPs) in the 3#-
untranslated region of the gene were genotyped and used for
ASE determination by pyrosequencing. After eliminating non-
informative samples and samples with RNA of insufﬁcient quality
109 cases and 125 controls were studied. Allelic ratios ranged
between 0.74 and 1.69 without evidence of bimodality or cutoff
points for ‘ASE’ versus ‘non-ASE’. Treating ASE as a continuous
variable, cases had non-signiﬁcantly different values than controls
(P 5 0.081 when comparing means by permutation test). How-
ever, cases had signiﬁcantly higher ASE values when compar-
ing medians by permutation test (P 5 0.0027) and when using
Wilcoxon test (P 5 0.0094). We conclude that with the present-
day technology, ASE differences between individuals and between
cases and controls are too subtle to be used to assess CRC risk.
More advanced technology is expected to resolve this issue as well
as the low informativity caused by the limited heterozygosity of
transcribed SNPs.
Introduction
Based on twin studies, colorectal cancer (CRC) displays  35% her-
itability (1). Case control studies suggest a ﬁrst-degree family risk
ratio  3 (2). Among all CRC patients, a positive family history of
colon cancer in a ﬁrst-or second-degree relative occurs in 20–
30%. High-penetrance susceptibility genes account for ,5% of all
CRC (3). In a recent review, it was concluded that 59% of the
population-attributable fraction of CRC predisposition could pres-
ently be accounted for when considering all or most genetic mecha-
nisms detected or proposed so far (4). This assessment included the
assumption that several recently discovered single-nucleotide poly-
morphism (SNP) associations with low or ultraloweffectsize detected
by genome-wide associationstudies (GWAS)would turn outto bereal
and account for 52% of the total population-attributable fraction. This
leaves  40% of the genetic predisposition unexplained. The putative
mutations have been hypothesized to be relatively rare (allele
frequency ,1%; not readily detectable by GWAS) and/or of low
but not ultralow effect size (odds ratio 2–5 and therefore not readily
detectable by linkage) (5).
These data lead to the assumption that the remaining predisposing
genes can be found neither by GWAS nor by linkage analysis. There is
some hope that whole genome sequencing will eventually provide
the answers; however, at present, the preferred way of ﬁnding such
intermediate-effect size gene mutations is the candidate gene ap-
proach. The transforming growth factor-b pathway is heavily involved
in CRC (6,7). Of the two receptors, the type 2 receptor has been
conclusively implicated as a tumor suppressor in CRC (8), whereas
the type 1 receptor has received less attention. Recently, when Tgfbr1
was knocked out in mice, homozygous loss was lethal but heterozy-
gous loss conferred no speciﬁcphenotype.When heterozygousknock-
out mice were bred into mice heterozygous for the ApcMin mutation,
the double mutants acquired an  2-fold increase in the number of
intestinal adenomas in comparison with ApcMin mice, and importantly,
the Tgfbr1þ/ ;ApcMin/þ mice acquired colonic carcinomas, suggesting
that haploinsufﬁciency for Tgfbr1 predisposes to colon cancer (9).
Allele-speciﬁc expression (ASE) was recently mentioned as a mu-
tational mechanism with phenotypic consequences (10). Contrary to
the common concept that the two alleles of a locus are equally ex-
pressed, ASE means that one allele is expressed at a lower level than
the other or conversely one is expressed at a higher level than the
other. Driven by these ﬁndings, we used the SNaPshot technology to
study the ASE of TGFBR1 in unaffected human tissue (blood) and
found that moderately lowered expression from one allele was a mea-
surable quantitative trait that was more common in CRC patients
( 10%) than in controls ( 1.5%) (11). This ASE of TGFBR1 could,
if conﬁrmed in larger populations, be interpreted to account for as
much as 10% of the population-attributable fraction. To validate the
ﬁndings, an alternative method based on pyrosequencing was applied
to a smaller series of lymphoblastoid cells from familial CRC patients
and controls from another cohort. In this experiment,the proportion of
ASE in CRC patients was lower (2 of 50 cases) when the same cutoff
(ASE ratio 1.5) was applied (12). This prompted us to undertake the
present experiments to further explore ASE of TGFBR1.
Material and methods
CRC cases and controls
The patients belonged to a series of 1566 consecutively ascertained, unselected
consenting CRC cases diagnosed in 1999–2004 in the six main hospitals in
metropolitan Columbus, Ohio (13,14). These hospitals perform the vast ma-
jority of operations for CRC or suspected CRC in the Columbus, Ohio, met-
ropolitan area (population, 1.5 million). The research protocol and consent
form were approved by the institutional review board at each participating
hospital, and all patients provided written informed consent. Cases of familial
adenomatous polyposis or the rare polyposis syndromes were not accrued.
Microsatellite instability-positive cases were excluded from the study. Totally
960 cases were considered for this study.
The control samples (n 5 900) were provided by the Ohio State University
Medical Center’s Human Genetics Sample Bank, which is a collection of
control samples for use in human genetics research that includes both donors’
anonymized biological specimens and linked phenotypic data. The data and
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for Genetics Research Studies’, which is approved by the Biomedical Sciences
Institutional Review Board at Ohio State University Medical Center. Recruit-
ment takes place in Ohio State University Medical Center primary care and
internal medicine clinics. If individuals agree to participate, they provide writ-
ten informed consent, complete a questionnaire, which includes demographic,
medicalandfamilyhistoryinformation,anddonateabloodsample.Asa result,
the controlswere derived from the same Columbus-area populationas the CRC
patients. After removing cases and controls due to the lack of informative
markers and/or insufﬁcient RNA quantity or quality, the ASE study was
performed on 109 cases and 125 controls. Cases and controls were frequency
matched by age groups:  45, 46–55, 56–65, 66–75 and  76 with Chi-square
P-value 5 0.053. The median age of the informative cases was 61 years and of
the controls 58 years with Wilcoxon rank sum test (P-value 5 0.060). Permu-
tation testing of the age showed variable signiﬁcance between cases and con-
trols when comparing means (P 5 0.015) and medians (P 5 0.208).
Agerangeforinformativecases was32–89years,whereasforthecontrols,it
was 18–94 years. Ethnicity in the cases was 95.4% Caucasian and 4.6%
African–American, and in the controls, 89% Caucasian and 11% African–
American (Chi-square test P-value 5 0.108). There were 48% females among
the cases and 50% among the controls (Chi-square test P-value 5 0.47).
DNA–RNA extraction, RNA quality and complementary DNA synthesis
Extraction of genomic DNA from peripheral blood was performed by a stan-
dard phenol–chloroform procedure. For total RNA extraction, cells were pro-
cessed with TRIzol reagent (Invitrogen, Carlsbad, CA). Samples for the RNA
extraction were stored either as dry white blood cell pellets or as cells lysed in
TRIzol. The quality of total RNA was checked using the Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA). We determined the RNA
Integrity Number (RIN) of each sample and it emerged that RNA extracted
from frozen pellets was often highly degraded (RIN , 3.0), whereas the RNA
obtained from TRIzol fractions was generally good (RIN . 8.0). For the
purpose of the ASE study, we chose only samples with a RIN of  6.0 (15).
Total RNAwas treated with DNase I (DNAfreeTM; Ambion, Austin, TX) prior
to reverse transcriptionwith AMVReverseTranscriptase(Roche, Indianapolis,
IN) using a gene-speciﬁc primer annealing to the 3#-end of the most down-
stream amplicon (containing SNP rs1590) used in the ASE analysis.
Genotyping samples for informativity
Withpresent-daymethods,ASE canonlybe readilydetermined in samplesthat
are heterozygous for SNPs residing in the transcribed sequence of the gene.
For large-scale ASE assessment, the markers must be reproducibly typeable
and reasonably informative. In TGFBR1, there are only ﬁve such SNPs; their
minor allele frequencies range from 9 to 38%. All ﬁve markers are in the 3#-
untranslated region as shown in Figure 1. The markers comprise three that
are in strong linkage disequilibrium (LD) with each other (LD group 1; R2 .
0.95) and two that are in equally strong LD with one another (LD group 2;
R2 . 0.95) but only partial LD with group 1 (R2 5 0.68). We typed the
markers in LD group 1 (rs334348, rs334349 and rs1590) and LD group 2
(rs868 and rs420549). For the genotyping, two polymerase chain reaction
(PCR) amplicons were obtained from genomic DNA for each sample using
GoldTaq polymerase (PE Applied Biosystems, Foster City, CA) in the
presence of 5%dimethyl sulfoxide. The ﬁrst amplicon contained SNPs
rs868 and rs334348 (forward: 5#-CAGCTTTGCCTGAACTCTCC-3# and
reverse: 5#-TGCAAAAGCTTGATGTGAGAA-3#) and the second amplicon
contained SNPs rs334349, rs420549 and rs1590 (forward: 5#-
ACCTGCTCTCCTGCTTGCT-3# and reverse: 5#-CTGTAGACAGGTCCAT-
CATGC-3#). The PCR conditions included 36 cycles of 95C for 15 s, 56C for
15 s and 72C for 60 s (ﬁrst amplicon)or 120 s (second amplicon).Multiplexed
SNaPshot reactions were performed on amplicon one and amplicon two using
two or three extension primers, respectively. Extension primers used were:
rs868, 5#-CTCTCAGTGAGGTAGAACAA-3#; rs334348, 5#-CTTGAT-
GTGAGAATATTCAAACATGA-3#; rs420549, 5#-TTGTTGTGCACTCT-
AACGAT-3#; rs1590, 5#-GAGATCACCTGTAGACAGGTCCATCA-3# and
rs334349 5#-CCCTGACGCAGAGACC-3#. Roughly 29% of samples were
informative for LD group 1 and 11% of samples were informative for all ﬁve
SNP markers.
Pyrosequencing and allele quantitation
For the samples in which all ﬁve SNPs were informative, three SNP markers
were used for pyrosequencing: rs868, rs334348 and rs334349. When samples
were only informative for SNPs in LD group 1, all three SNP markers were
used, whereas in the case of SNPs in LD group 2, both markers were used. For
each SNP, the PCR reactions for DNA and RNAwere performed in triplicates
in a 30 ll reaction volume using AmpliTaq Gold polymerase (PE Applied
Biosystems). Primers and PCR conditions were as described (12).
After PCR, the DNA and RNA ampliﬁcation products were sequenced using
the sequencing primers (12) on a PyroMark, MD pyrosequencing instrument
(QIAGEN, Chatsworth, CA) as per the manufacturer’s instructions. The pro-
portions of individual alleles for each SNP were obtained using the PyroMark
MD software package (QIAGEN) and the ratio of allele 1 versus allele 2 in the
DNA and RNAwas then calculated. The results of triplicate measurements for
each single SNP for DNA and RNAwere averaged and the standard deviation
(SD) was calculated. In only 8% of the measurements, the SD exceeded a value
of 0.1. The ﬁnal ASE ratio for each SNP of each sample measured was calcu-
lated using the formula: ASE ratio 5 RNA (allele 1 expression/allele 2 expres-
sion)/genomic DNA (allele 1 expression/allele 2 expression). For the ﬁve SNPs
used, the (allele 1/allele 2) was as follows: rs868 (A/G), rs334348 (T/C),
rs334349 (C/T), rs1590 (T/G) and rs420549 (C/G). For each sample, the ﬁnal
ASE value was calculated as the median of the ASE values for two or three
SNPs typed (see supplementary Table S1, available at Carcinogenesis Online).
To validate the use of pyrosequencing for ASE measurements, mixing ex-
periments were performed in which DNA homozygous for allele 1 was mixed
in known proportions with DNA homozygous for allele 2. The purpose was to
establish whether the peak strengths of the two alleles are comparable at
different proportions of the two alleles. Results from four of the SNPs are
shown graphically in Figure 2. A consistent rectilinear correlation between
input of the two allelic variants and the resulting ratio is demonstrated.
Statistical analysis
The nonparametric Wilcoxon rank sum test was used to compare ASE values
between cases and controls. Moreover, the means and the medians of the two
groups were compared using a permutation test with 100 000 permutations.
All tests were two sided. The ethnicity, gender and age group distributions
between cases and controls were compared using Chi-squared test.
Results
The ASE values of the cases and controls are shown in Figure 3A. The
valuesrangefrom0.74to1.69,withtwocasesandtwocontrols having
values  1.5, the cutoff previously suggested to distinguish between
ASE and non-ASE based on a receiver operating characteristic anal-
ysis (11). The visual impression of the scatter plot does not suggest
any obvious cutoff point or bimodality in the data. The receiver op-
erating characteristic analysis estimating the sensitivity, speciﬁcity
and the Youden’s index deﬁned as ‘sensitivity þ speciﬁcity 1’ that
measures the overall diagnostic accuracy of varied cutoff points was
performed (Table I). The best cutoff was obtained by maximizing
Youden’s index at ASE value of 1.1, which signiﬁes a roughly 10%
difference in expression between the two alleles.
Comparison of high (ASE   1.1 and ASE   0.9) and low (0.9 ,
ASE , 1.1) ASE between the case and control groups was done by
applying a univariate logistic regression analysis (odds ratio 5 1.68,
P-value 5 0.055). This suggests that with the methods used here,
classifying cases and controls as ASE versus non-ASE is not feasible.
Fig. 1. Diagram of the TGFBR1 genomic region. Shown are the locations of the ﬁve SNPs in the 3#-untranslated region used for ASE determination.
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between cases and controls shows a signiﬁcantly higher ASE value in
cases than in controls (P 5 0.0094 by Wilcoxon test), whereas the
permutation testing is borderline (P 5 0.081) when comparing
means. Permutation testing comparing medians results in a signiﬁ-
cantly higher ASE value in cases than in controls (P 5 0.0027).
Joint evaluation of ASE values . and ,1 is problematic since
a value of 1.1 corresponds to a value of 0.9 but the statistical analysis
does not give the same weight to these two reciprocal values.
To overcome this problem, values ,1 were reciprocally converted
as shown in Figure 3B. Analyzing the differences in this way, ASE
values in cases are higher than in controls (P 5 0.0064) by Wilcoxon
test and borderline (P 5 0.077) using permutation testing when com-
paring means. Permutation testing comparing medians showed a sig-
niﬁcantly higher ASE value in cases than in controls (P 5 0.0070).
There was no difference in ASE values between older and younger
CRC cases (median cut, Wilcoxon test P 5 0.82 and Permutation
test, based on medians P 5 0.48).
Discussion
While conducting our ﬁnal analysis, the results of two studies on ASE
of TGFBR1 were published. In the ﬁrst study, no evidence of an
association between TGFBR1 polymorphisms and CRC risk was de-
tected, and ASE was reported to be equally rare in cases as in con-
trols (16). In the second study, ASE was found in  10% (10/98) of all
Caucasian and 7% (1/14) of all African–American patients; however,
there were no healthy controls studied for comparison (17). An asso-
ciation between ASE and three SNPs in TGFBR1 was noted. Whereas
the ﬁrst study apparently contradicts our ﬁndings, the second study
Fig. 3. TGFBR1 ASE distribution in 109 CRC patients and 125 controls studied by pyrosequencing. (A) ASE values obtained from pyrosequencing. (B) The same
data shown after ASE values ,1.0 have been transformed to their reciprocals. Superscript numerals with probability values refer to the following: 1, Paired
Wilcoxon test; 2, permutation test comparing means; and 3, permutation test comparing medians.
Fig. 2. Accuracy of pyrosequencing to quantify the two alleles of SNPs. Genomic DNAwas extracted from cells homozygous for either allele of the SNP markers
and quantiﬁed using NanoDrop. For each SNP, the two DNAs representing the alternative alleles were mixed at different ratios to simulate expected allele ratios.
PCR was performed on each mixture, followed by pyrosequencing to determine the observed allelic ratios. Pearson’s correlation test is used to calculate the
P-value.
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results. How can such contrasting results be explained?
There are major differences between our present study and the
three published reports referred to above. Firstly, all three studies
were conducted using the SNaPshot technology that we have found
to give inconsistent results as evidenced by considerably larger
SDs compared with the pyrosequencing method (SNaPshot:
median SD 5 0.13, average SD 5 0.15; pyrosequencing: median
SD 5 0.076, average SD 5 0.094). Secondly, in our previous
study (11), we had included SNP rs7871490 that accounted
for  35% informative cases and  28% informative controls. This
SNP resides in a region of repetitive sequence. Our repeated at-
tempts with SNaPshot yielded inconsistent results, possibly due to
polymerase slippage. We therefore elected to remove SNP
rs7871490 from the study. We note that a signiﬁcant number of
ASE-positive cases in reference (11) stem from results using this
marker. Thirdly, using microsatellites such as the 9A/6A marker
(16) to measure ASE has not proven to be reproducible in our
hands. Fourthly, we have noticed that high-quality RNA is essential
for reproducibility of ASE. Even just somewhat degraded RNA can
produce inconsistent results with either method.
In our current study, 49 cases were the same as in our previous
study and they consistently showed lower ASE ratios by pyrosequenc-
ing (supplementary Figure S1 is available at Carcinogenesis Online;
paired Wilcoxon test P 5 6.747e-06). However, the calculation of
ASE differed between our two studies. In the present study, the
ASE value for each sample was calculated as a median value of at
least two or three SNPs (see Materials and Methods; supplementary
Table S1 is available at Carcinogenesis Online). In Valle et al. (11),
ASE was calculated as the average of measurements across multiple
SNPs obtained for each sample. In this way, one exceptionally high
measurement (‘outlier’) can bias the ASE ratio and we realized that
this had pertained in particular to SNP rs7871490. However, even
after removing rs7871490, we observe a bias using SNaPshot
that evidently exaggerates the allelic differences. (supplementary
Figure S1 is available at Carcinogenesis Online). Thus, the difference
in ASE results between this study and those reported before
(11,12,16,17) originates in different strategies and methods, possibly
study populations and numbers of studied individuals. While such
differences may explain some of the incongruity, we wish to raise
here the possibility that none of the present methods are sensitive
enough to measure subtle ASE on a case-by-case basis.
Our present ﬁndings support the notion that the two alleles in
TGFBR1 are not always equally expressed, constituting a subtle quan-
titative trait that is weakly associated with the risk for CRC. However,
our results suggest that the unequal expression of TGFBR1 from the
two alleles in a given individual cannot be used to classify the in-
dividual as unequivocally ASE positive or ASE negative as we sug-
gested previously (11). At the present time, this precludes ASE from
being used as a predictive marker of CRC risk until a genomic cause
for ASE can be determined. Nevertheless, to assess ASE, pyrose-
quencing has proven to be more robust than SNaPshot in direct com-
parison.
The fact that the ASE phenomenon is widespread not only in
humans (10,18) and mice (19) but also in most organisms is
becoming well known and widely publicized (20,21). Moreover, the
differential expression of alleles in autosomal loci is often inherited
and can be highly context-speciﬁc (22). We show that ASE
of TGFBR1 is slightly more common in patients with CRC than in
controls. ASE as a cause of disease predisposition has been docu-
mented before, for instance, regarding the APC gene in familial
adenomatous polyposis (23) and the DAPK1 gene in chronic lympho-
cytic leukemia (24). Further examples are being proposed and re-
ported increasingly, e.g. ASE of BRCA1 contributing to breast
cancer (25). Notably, in most of the cases referred to, the
putative genomic cause of the ASE phenomenon has so far been
elusive.
The extreme subtlety of the expression differences that we describe
should be kept in mind. A more deﬁnitive evaluation of the ASE
phenomenon in TGFBR1 will probably only come with technological
and conceptual advances that will allow greater precision and circum-
vent the need for naturally occurring transcribed SNPs as an obliga-
tory tool. We note that with the present technology, it is possible to
score an ASE value in only approximately one-third of all individuals
at best, leaving open the possibility that ASE occurs or does not occur
preferentially in those individuals who are uninformative for the rel-
evant SNPs.
With the present limitations (lack of informativity; lack of a cutoff
ratio deﬁning ASE), it is challenging to try to clarify the underlying
putative constitutional (‘germ line’, ‘genomic’) cause of ASE. We
previously sequenced some 96 kb of genomic DNA comprising
TGFBR1 and adjacent sequence in six CRC patients classiﬁed as
having ASE. This led to the detection of some 200 sequence changes,
mainly SNPs, of which approximately half were not listed in the
databases. However, no particular sequence change stood out as being
a probable candidate for an ASE-causing mutation (11). Similarly,
exonic sequencing of 96 CRC patients by others failed to identify any
probable mutations (16).
Hence, the cause of ASE of TGFBR1 remains unresolved. It is
presently not clear if the cause is in cis or in trans. It is also totally
unclear if an expression difference between the two alleles per se is
relevant or if the sum of the expression level is important. Further-
more, it remains obscure how small allelic imbalances could cause
a phenotype. However, there are now several precedents that subtle
gene expression differences can have a signiﬁcant phenotypic im-
pact. GWAS have implicated SMAD7 as a locus for CRC risk (26).
Functional analysis of a novel intronic SNP in the gene showed that
a very small difference in expression levels of just 11% between the
two alleles was detectable and associated with a 1.4-fold elevated
CRC risk (27). This is also apparently true for a SNP (rs6983267) in
chromosome band 8q24 that is associated with an increased risk for
CRC (28,29,30). The underlying mechanism was suggested to be
a different binding afﬁnity of the two alleles for a transcription
factor that affects the locus’ function as a transcriptional enhancer
(31,32). Again, the experimental difference between the two alleles
was of the order of only 30%. At this point, we do not know which if
any of the variants around TGFBR1 is responsible for ASE in cis.
Moreover, we have not seen any indication that ASE of TGFBR1 is
age-related or tissue-type speciﬁc but more studies along these lines
are expected.
Supplementary material
Supplementary Figure S1 and Table S1 can be found at http://carcin
.oxfordjournals.org/
Table I. Sensitivity, speciﬁcity and Youden’s index for different ASE cutoff
values
ASE cutoff Sensitivity Speciﬁcity Youden’s index
1.00 1 0 0
1.05 0.706 0.432 0.138
1.10 0.468 0.672 0.140
1.15 0.257 0.808 0.065
1.20 0.165 0.840 0.005
1.25 0.128 0.912 0.040
1.30 0.101 0.952 0.053
1.35 0.073 0.968 0.041
1.40 0.046 0.968 0.014
1.45 0.046 0.968 0.014
1.50 0.018 0.992 0.010
1.55 0.018 0.992 0.010
1.60 0 0.992  0.008
1.65 0 0.992  0.008
1.70 0 1 0
The cutoff with the highest Youden’s index is bolded.
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